

George Dimopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4207694/publications.pdf>

Version: 2024-02-01

175
papers

12,779
citations

30551

56
h-index

30277

107
g-index

182
all docs

182
docs citations

182
times ranked

17627
citing authors

#	ARTICLE	IF	CITATIONS
1	Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. <i>Cell Host and Microbe</i> , 2020, 27, 992-1000.e3.	5.1	1,746
2	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
3	Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. <i>European Respiratory Journal</i> , 2016, 47, 45-68.	3.1	654
4	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. <i>Intensive Care Medicine</i> , 2020, 46, 1127-1153.	3.9	504
5	A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 56-64.	2.5	497
6	Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. <i>Critical Care</i> , 2015, 19, 7.	2.5	310
7	Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis. <i>Cell Host and Microbe</i> , 2020, 28, 117-123.e1.	5.1	210
8	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 52-59.	1.1	188
9	Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, i5-i14.	1.3	178
10	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
11	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. <i>Intensive Care Medicine</i> , 2015, 41, 1601-1610.	3.9	165
12	<i>Candida Albicans</i> Versus Non- <i>Albicans</i> Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome. <i>Anesthesia and Analgesia</i> , 2008, 106, 523-529.	1.1	163
13	Attributable mortality of <i>Stenotrophomonas maltophilia</i> infections: a systematic review of the literature. <i>Future Microbiology</i> , 2009, 4, 1103-1109.	1.0	152
14	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. <i>Intensive Care Medicine</i> , 2016, 42, 1958-1969.	3.9	151
15	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically Ill Patients*. <i>Critical Care Medicine</i> , 2014, 42, 601-609.	0.4	150
16	Risk factors for target non-attainment during empirical treatment with β -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.	3.9	147
17	Low-Dose Vasopressin in the Treatment of Septic Shock in Sheep. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 481-486.	2.5	140
18	Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: Results of a knowledge test among 3405 European intensive care nurses*. <i>Critical Care Medicine</i> , 2009, 37, 320-323.	0.4	138

#	ARTICLE	IF	CITATIONS
19	A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia. <i>Chest</i> , 2017, 151, 1239-1246.	0.4	136
20	Management of KPC-producing <i>Klebsiella pneumoniae</i> infections. <i>Clinical Microbiology and Infection</i> , 2018, 24, 133-144.	2.8	136
21	Task force on management and prevention of <i>Acinetobacter baumannii</i> infections in the ICU. <i>Intensive Care Medicine</i> , 2015, 41, 2057-2075.	3.9	133
22	Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia. <i>Drugs</i> , 2008, 68, 1841-1854.	4.9	132
23	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	1.3	129
24	Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia. <i>Chest</i> , 2013, 144, 1759-1767.	0.4	127
25	ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. <i>Intensive Care Medicine</i> , 2019, 45, 789-805.	3.9	127
26	Impact of patient position on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. <i>Journal of Critical Care</i> , 2009, 24, 515-522.	1.0	125
27	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. <i>Intensive Care Medicine</i> , 2017, 43, 1225-1238.	3.9	123
28	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. <i>Critical Care</i> , 2019, 23, 219.	2.5	123
29	Community-acquired <i>Stenotrophomonas maltophilia</i> infections: a systematic review. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2009, 28, 719-730.	1.3	116
30	Invasive Fungal Infections in the ICU: How to Approach, How to Treat. <i>Molecules</i> , 2014, 19, 1085-1119.	1.7	116
31	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. <i>Intensive Care Medicine</i> , 2013, 39, 672-681.	3.9	114
32	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	2.5	108
33	An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. <i>Intensive Care Medicine</i> , 2012, 38, 940-949.	3.9	106
34	Heteroresistance: a concern of increasing clinical significance?. <i>Clinical Microbiology and Infection</i> , 2008, 14, 101-104.	2.8	105
35	Validation of the new Sepsis-3 definitions: proposal for improvement in early risk identification. <i>Clinical Microbiology and Infection</i> , 2017, 23, 104-109.	2.8	105
36	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017, 43, 1187-1197.	3.9	103

#	ARTICLE	IF	CITATIONS
37	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: “AbSe”, a multinational observational cohort study and ESICM Trials Group Project. <i>Intensive Care Medicine</i> , 2019, 45, 1703-1717.	3.9	103
38	Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among European intensive care nurses. <i>Journal of Hospital Infection</i> , 2008, 70, 180-185.	1.4	102
39	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	3.9	101
40	Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomised controlled trials. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 543-552.	4.6	94
41	Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. <i>Critical Care</i> , 2012, 16, R149.	2.5	94
42	Therapeutic options for <i>Burkholderia cepacia</i> infections beyond co-trimoxazole: a systematic review of the clinical evidence. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 394-404.	1.1	87
43	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	2.5	87
44	Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. <i>Clinical Microbiology and Infection</i> , 2011, 17, E9-E11.	2.8	86
45	Post mortem examination in the intensive care unit: still useful?. <i>Intensive Care Medicine</i> , 2004, 30, 2080-2085.	3.9	85
46	Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2008, 27, 439-443.	1.3	80
47	Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 377-384.	1.3	74
48	Potential risk factors for infection with <i>Candida</i> spp. in critically ill patients. <i>Clinical Microbiology and Infection</i> , 2004, 10, 550-555.	2.8	72
49	A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. <i>Clinical Infectious Diseases</i> , 2015, 61, civ707.	2.9	72
50	Early Switch to Oral Treatment in Patients with Moderate to Severe Community-Acquired Pneumonia. <i>Drugs</i> , 2008, 68, 2469-2481.	4.9	70
51	Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Coronavirus. <i>Shock</i> , 2020, 54, 633-637.	1.0	68
52	Ventilator-Associated Pneumonia. <i>Chest</i> , 2008, 133, 625-632.	0.4	67
53	Viral epidemiology of acute exacerbations of chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 12-18.	1.1	67
54	Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. <i>Journal of Infection</i> , 2011, 63, 344-350.	1.7	65

#	ARTICLE	IF	CITATIONS
55	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 289-293.	1.1	63
56	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	1.4	59
57	Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. <i>Critical Care</i> , 2016, 20, 53.	2.5	59
58	Invasive aspergillosis in the intensive care unit. <i>Annals of the New York Academy of Sciences</i> , 2012, 1272, 31-39.	1.8	58
59	Treatment of invasive candidiasis in the elderly: a review. <i>Clinical Interventions in Aging</i> , 2013, 8, 1199.	1.3	58
60	Comparison of First-Line With Second-Line Antibiotics for Acute Exacerbations of Chronic Bronchitis. <i>Chest</i> , 2007, 132, 447-455.	0.4	57
61	Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 442-450.	1.3	56
62	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. <i>International Journal of Antimicrobial Agents</i> , 2009, 33, 554.e1-554.e7.	1.1	55
63	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. <i>Intensive Care Medicine</i> , 2020, 46, 1404-1417.	3.9	54
64	Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Care, 2019, 23, 383.	2.5	53
65	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <sc>FUN</sc>gal infections Definitions in <sc>ICU</sc> patients (<sc>FUNDICU</sc>) project. <i>Mycoses</i> , 2019, 62, 310-319.	1.8	53
66	Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesity. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108331.	1.1	53
67	Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. <i>Epidemiology and Infection</i> , 2011, 139, 27-40.	1.0	52
68	A Visual and Comprehensive Review on COVID-19-Associated Pulmonary Aspergillosis (CAPA). <i>Journal of Fungi</i> (Basel, Switzerland), 2021, 7, 1067.	1.5	52
69	Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis. <i>European Respiratory Journal</i> , 2007, 29, 1127-1137.	3.1	51
70	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. <i>Intensive Care Medicine</i> , 2017, 43, 509-518.	3.9	51
71	Clinical Significance of the Pharmacokinetic and Pharmacodynamic Characteristics of Tigecycline. <i>Current Drug Metabolism</i> , 2009, 10, 13-21.	0.7	49
72	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 423-430.	1.1	48

#	ARTICLE	IF	CITATIONS
73	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. <i>BMC Infectious Diseases</i> , 2012, 12, 152.	1.3	47
74	Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. <i>Critical Care</i> , 2005, 9, R508.	2.5	46
75	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. <i>Journal of Critical Care</i> , 2011, 26, 331.e1-331.e7.	1.0	44
76	Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients. <i>Clinical Microbiology and Infection</i> , 2012, 18, 680-687.	2.8	44
77	Polymicrobial bloodstream infections: Epidemiology and impact on mortality. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 207-212.	0.9	43
78	Fluoroquinolones compared with β -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. <i>Cmaj</i> , 2008, 178, 845-854.	0.9	41
79	Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. <i>Future Microbiology</i> , 2014, 9, 1053-1069.	1.0	41
80	Chemotherapy-induced neutropenia in lung cancer patients: The role of antibiotic prophylaxis. <i>Cancer Letters</i> , 2011, 313, 9-14.	3.2	40
81	Kinetics of circulating fetuin-A may predict mortality independently from adiponectin, high molecular weight adiponectin and prognostic factors in critically ill patients with sepsis: A prospective study. <i>Journal of Critical Care</i> , 2017, 41, 78-85.	1.0	40
82	COVID-19-Associated Pulmonary Aspergillosis (CAPA). <i>Journal of Intensive Medicine</i> , 2021, 1, 71-80.	0.8	40
83	Are infections due to resistant pathogens associated with a worse outcome in critically ill patients?. <i>Journal of Infection</i> , 2003, 47, 307-316.	1.7	38
84	Controversies in the management of the critically ill: the role of probiotics. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, S41-S44.	1.1	37
85	Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study. <i>Journal of the American Geriatrics Society</i> , 2013, 61, 2065-2071.	1.3	34
86	Optimal Adrenergic Support in Septic Shock Due to Peritonitis. <i>Anesthesiology</i> , 2003, 98, 888-896.	1.3	33
87	Gut mucosal damage during endotoxic shock is due to mechanisms other than gut ischemia. <i>Journal of Applied Physiology</i> , 2003, 95, 2047-2054.	1.2	33
88	Inhaled corticosteroids and <i>Aspergillus fumigatus</i> isolation in cystic fibrosis. <i>Medical Mycology</i> , 2014, 52, 715-722.	0.3	33
89	AME evidence series 001â€”The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital. <i>Journal of Thoracic Disease</i> , 2016, 8, 2654-2665.	0.6	33
90	Is <i>Candida</i> really a threat in the ICU?. <i>Current Opinion in Critical Care</i> , 2008, 14, 600-604.	1.6	32

#	ARTICLE	IF	CITATIONS
91	Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. <i>Critical Care</i> , 2013, 17, R289.	2.5	32
92	How to treat fungal infections in ICU patients. <i>BMC Infectious Diseases</i> , 2015, 15, 205.	1.3	32
93	Circulating eNamt and resistin as a proinflammatory duet predicting independently mortality in critically ill patients with sepsis: A prospective observational study. <i>Cytokine</i> , 2019, 119, 62-70.	1.4	30
94	Cerebral aspergillosis in adult critically ill patients: a descriptive report of 10 patients from the AspiCU cohort. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 165-169.	1.1	27
95	A 10-Year Survey of Antifungal Susceptibility of Candidemia Isolates from Intensive Care Unit Patients in Greece. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1242-1244.	1.4	25
96	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 1912-1918.	2.9	24
97	The haemostatic profile in critically ill COVID-19 patients receiving therapeutic anticoagulant therapy. <i>Medicine (United States)</i> , 2020, 99, e23365.	0.4	24
98	Blood Warming during Hemofiltration Can Improve Hemodynamics and Outcome in Ovine Septic Shock. <i>Anesthesiology</i> , 2006, 104, 1216-1222.	1.3	23
99	How to select an antifungal agent in critically ill patients. <i>Journal of Critical Care</i> , 2013, 28, 717-727.	1.0	23
100	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.	1.4	23
101	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 1052-1059.	1.0	22
102	Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 211-229.	2.0	22
103	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRs project. <i>ERJ Open Research</i> , 2017, 3, 00092-2017.	1.1	22
104	New treatments of multidrug-resistant Gram-negative ventilator-associated pneumonia. <i>Annals of Translational Medicine</i> , 2018, 6, 423-423.	0.7	22
105	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2020, 39, 723-730.	0.6	22
106	ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , 2022, 14, 218-228.	1.8	21
107	H1N1v influenza vaccine in Greek medical students. <i>European Journal of Public Health</i> , 2011, 21, 329-332.	0.1	20
108	Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 102.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD?. <i>European Respiratory Journal</i> , 2017, 50, 1700532.	3.1	17
110	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 201-210.	2.0	17
111	Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group. <i>Infectious Diseases and Therapy</i> , 2020, 9, 407-416.	1.8	17
112	Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1779-1792.	1.8	17
113	Efficacy and safety of anidulafungin in elderly, critically ill patients with invasive <i>Candida</i> infections: a post hoc analysis. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 521-526.	1.1	16
114	Elderly versus nonelderly patients with invasive aspergillosis in the ICU: a comparison and risk factor analysis for mortality from the AspICU cohort. <i>Medical Mycology</i> , 2018, 56, 668-678.	0.3	16
115	Approach to the Febrile Patient in the ICU. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 471-484.	1.9	15
116	Synergistic interactions between colistin and meropenem against extensively drug-resistant and pandrug-resistant <i>Acinetobacter baumannii</i> isolated from ICU patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 670-671.	1.1	15
117	Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. <i>Annals of Intensive Care</i> , 2017, 7, 9.	2.2	15
118	Comparison of Clinical Manifestation, Diagnosis, and Outcomes of Invasive Pulmonary Aspergillosis and Pulmonary Mucormycosis. <i>Microorganisms</i> , 2019, 7, 531.	1.6	15
119	<i>Clostridioides difficile</i> (formerly <i>Clostridium difficile</i>) infection in the critically ill: an expert statement. <i>Intensive Care Medicine</i> , 2020, 46, 215-224.	3.9	15
120	Use of IFN γ /IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock. <i>Frontiers in Immunology</i> , 2021, 12, 607217.	2.2	15
121	Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. <i>Minerva Anestesiologica</i> , 2015, 81, 405-18.	0.6	14
122	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106591.	1.1	14
123	Duration of pneumonia therapy and the role of biomarkers. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 221-225.	1.3	13
124	Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units. <i>Drugs</i> , 2021, 81, 1065-1078.	4.9	13
125	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 827-840.	1.8	13
126	Understanding antibiotic stewardship for the critically ill. <i>Intensive Care Medicine</i> , 2016, 42, 2063-2065.	3.9	12

#	ARTICLE	IF	CITATIONS
127	Penicillins vs trimethoprim-based regimens for acute bacterial exacerbations of chronic bronchitis: meta-analysis of randomized controlled trials. <i>Canadian Family Physician</i> , 2009, 55, 60-7.	0.1	12
128	What is new in the use of aminoglycosides in critically ill patients?. <i>Intensive Care Medicine</i> , 2014, 40, 1553-1555.	3.9	11
129	Haplotypes composed of minor frequency single nucleotide polymorphisms of the TNF gene protect from progression into sepsis: A study using the new sepsis classification. <i>International Journal of Infectious Diseases</i> , 2018, 67, 102-106.	1.5	11
130	<i>Candida albicans</i> chronic colonisation in cystic fibrosis may be associated with inhaled antibiotics. <i>Mycoses</i> , 2015, 58, 416-421.	1.8	10
131	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 907-918.	1.0	10
132	<i>Scenedosporium apiospermum</i> complex in cystic fibrosis; should we treat?. <i>Mycoses</i> , 2017, 60, 594-599.	1.8	10
133	Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e74-e87.	4.6	10
134	Past history of stage I/II solid tumor malignancy impacts considerably on sepsis mortality: a propensity score matching analysis from the hellenic sepsis study group. <i>BMC Infectious Diseases</i> , 2019, 19, 831.	1.3	9
135	A Severe COVID-19 Case Complicated by Right Atrium Thrombus. <i>American Journal of Case Reports</i> , 2020, 21, e926915.	0.3	9
136	Fungal Infections in Critically Ill COVID-19 Patients: Inevitable Malum. <i>Journal of Clinical Medicine</i> , 2022, 11, 2017.	1.0	9
137	In 2035, will all bacteria be multiresistant? Yes. <i>Intensive Care Medicine</i> , 2016, 42, 2014-2016.	3.9	8
138	Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. <i>Minerva Anestesiologica</i> , 2017, 83, 1126-1136.	0.6	8
139	L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia. <i>American Journal of Case Reports</i> , 2013, 14, 311-314.	0.3	8
140	Duration of therapy of ventilator-associated pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2016, 29, 218-222.	1.3	7
141	Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. <i>Clinical Microbiology and Infection</i> , 2016, 22, 719-724.	2.8	7
142	Comparative pharmacokinetics of the three echinocandins in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2969-2976.	1.3	7
143	Invasive Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 851-861.	0.8	7
144	Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1024-1032.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Immediate post-operative effects of tracheotomy on respiratory function during mechanical ventilation. <i>Critical Care</i> , 2004, 8, R243.	2.5	6
146	Post-operative <i>Aspergillus</i> mediastinitis in a man who was immunocompetent: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 312.	0.4	6
147	“Salvage treatment” for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. <i>Intensive Care Medicine</i> , 2017, 43, 1164-1166.	3.9	6
148	An overview on severe infections in Europe. <i>Intensive Care Medicine</i> , 2017, 43, 686-689.	3.9	6
149	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. <i>Drugs</i> , 2017, 77, 1399-1412.	4.9	6
150	Drivers and impact of antifungal therapy in critically ill patients with <i>Aspergillus</i> -positive respiratory tract cultures. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 529-535.	1.1	6
151	TB or not TB: update from the ERS Respiratory Infection Assembly 10. <i>European Respiratory Journal</i> , 2010, 36, 665-670.	3.1	5
152	Understanding resistance in <i>Pseudomonas</i> . <i>Intensive Care Medicine</i> , 2020, 46, 350-352.	3.9	5
153	Meta-analyses on the Prevention and Treatment of Respiratory Tract Infections. <i>Infectious Disease Clinics of North America</i> , 2009, 23, 331-353.	1.9	4
154	Esmolol: immunomodulator in pyelonephritis by <i>Pseudomonas aeruginosa</i> . <i>Journal of Surgical Research</i> , 2015, 198, 175-184.	0.8	4
155	Endomyocardial and pericardial aspergillosis in critically ill patients. <i>Mycoses</i> , 2017, 60, 576-580.	1.8	4
156	Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose?. <i>Journal of Pharmacy and Pharmacology</i> , 2020, 72, 1750-1760.	1.2	4
157	Improving diagnostic accuracy for invasive pulmonary aspergillosis in the intensive care unit. <i>Annals of Translational Medicine</i> , 2016, 4, 352-352.	0.7	4
158	Characteristics, risk factors and outcomes of <i>Clostridium difficile</i> infections in Greek Intensive Care Units. <i>Intensive and Critical Care Nursing</i> , 2019, 53, 73-78.	1.4	3
159	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Using Validated Pharmacokinetic/Pharmacodynamic In Vivo Models To Further Evaluate Enzyme Functionality and Clinical Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0127421.	1.4	3
160	Invasive pulmonary aspergillosis in solid-organ transplant patients in the intensive care unit. <i>Transplant Infectious Disease</i> , 2022, 24, e13746.	0.7	3
161	Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.	2.9	2
162	What is new in infection prevention in critical care in 2014?. <i>Intensive Care Medicine</i> , 2014, 40, 1151-1154.	3.9	2

#	ARTICLE	IF	CITATIONS
163	Susceptibility profiles and clinical efficacy of antifungals against candida bloodstream isolates from critically ill patients: Focus on intravenous itraconazole. International Journal of Antimicrobial Agents, 2019, 54, 471-477.	1.1	2
164	Antibiotics Selection for Bacteremic Pneumonia. Chest, 2007, 132, 360-361.	0.4	1
165	Selection for Candida Non-albicans spp. After Fluconazole Use. Anesthesia and Analgesia, 2008, 107, 2091-2092.	1.1	1
166	Re: Semirecumbent position to prevent ventilator-associated pneumonia is not evidence based. Journal of Critical Care, 2010, 25, 153-154.	1.0	1
167	ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training. Breathe, 2018, 14, 269-275.	0.6	1
168	Propofol associated Brugada "like coved type electrocardiogram in a trauma patient with a fatal outcome. Acta Cardiologica, 2019, 74, 274-275.	0.3	1
169	Infections in elderly intensive care unit patients. Journal of Emergency and Critical Care Medicine, 2019, 3, 44-44.	0.7	1
170	Post mortem examination in the intensive care unit: still useful?. Intensive Care Medicine, 2005, 31, 312-312.	3.9	0
171	Yeast central nervous system infection in a critically ill patient: a case report. Journal of Medical Case Reports, 2014, 8, 253.	0.4	0
172	Antibiotic treatment and prevention of exacerbations of COPD. , 2013, , 96-106.		0
173	Kinetics of serum adiponectin and HMWA (High Molecular Weight Adiponectin), and mortality in ICU patients with sepsis. , 2017, , .		0
174	Circulating fetuin-A as a biomarker predicting mortality in ICU septic patients. , 2017, , .		0
175	When the duration of infusion does matter: the case of meropenem and piperacillin. Minerva Anestesiologica, 2014, 80, 1258-60.	0.6	0